OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer

c-MET is considered a driver of cancer progression, impacting tumor growth and tumor-supporting stroma. Here, we investigated the therapeutic efficacy of OMO-1, a potent and selective c-MET inhibitor, in an immunocompetent intraductal mouse model for triple-negative breast cancer (TNBC). OMO-1 reduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Steenbrugge, Jonas, Vander Elst, Niels, Demeyere, Kristel, De Wever, Olivier, Sanders, Niek N., Van Den Broeck, Wim, Ciamporcero, Eric, Perera, Timothy, Meyer, Evelyne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969607/
https://www.ncbi.nlm.nih.gov/pubmed/33731699
http://dx.doi.org/10.1038/s41523-021-00234-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969607/
https://www.ncbi.nlm.nih.gov/pubmed/33731699
http://dx.doi.org/10.1038/s41523-021-00234-8

Ejemplares similares